Clinical Trial Update: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous versus intravenous Rituxan in CD20+ diffuse large B-cell lymphoma and CD20+ follicular non-Hodgkin's lymphoma showed comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2016-08-29